| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ed28726de9f916f355f8adc331e736b8 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-042
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1825
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-18 |
| filingDate |
2016-10-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f2b13509c334d9c8bf51e42ec0d790bb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_35199b8e8fce6e10aa7043148af87211 |
| publicationDate |
2017-04-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2017096462-A1 |
| titleOfInvention |
Chimeric fgf21 proteins with enhanced binding affinity for beta-klotho for the treatment of type ii diabetes, obesity, and related metabolic disorders |
| abstract |
The present invention relates to chimeric proteins that include an N-terminus coupled to a C-terminus, where the N-terminus includes an N-terminal portion of fibroblast growth factor 21 (“FGF21”) and the C-terminus includes a C-terminal portion of fibroblast growth factor 19 (“FGF19”). The present invention also relates to pharmaceutical compositions including chimeric proteins according to the present invention, as well as methods for treating a subject suffering from diabetes, obesity, or metabolic syndrome, methods of treating a subject in need of increased FGF21-βKlotho-FGF receptor complex formation, methods of causing increased FGF21 receptor agonist-βKlotho-FGF receptor complex formation, and methods of screening for compounds with enhanced binding affinity for the βKlotho-FGF receptor complex involving the use of chimeric proteins of the present invention. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9907830-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10364278-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9926355-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9926356-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10703788-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10464979-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022257479-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10633424-B2 |
| priorityDate |
2012-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |